Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Xencor, Inc. (NASDAQ:XNCR) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $24.8750.

XNCR has been the topic of a number of research analyst reports. Cantor Fitzgerald boosted their price target on Xencor from $40.00 to $42.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. JPMorgan Chase & Co. reduced their price objective on shares of Xencor from $20.00 to $18.00 and set an “overweight” rating on the stock in a research report on Thursday, November 6th. Bank of America downgraded shares of Xencor from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $23.00 to $12.00 in a report on Wednesday, September 3rd. Royal Bank Of Canada raised their target price on shares of Xencor from $18.00 to $19.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a report on Monday.

Institutional Investors Weigh In On Xencor

A number of hedge funds have recently made changes to their positions in the company. Walleye Capital LLC purchased a new stake in shares of Xencor during the 2nd quarter worth approximately $1,955,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Xencor by 153.2% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 29,371 shares of the biopharmaceutical company’s stock valued at $231,000 after purchasing an additional 17,773 shares in the last quarter. Y Intercept Hong Kong Ltd increased its position in Xencor by 93.0% in the second quarter. Y Intercept Hong Kong Ltd now owns 95,745 shares of the biopharmaceutical company’s stock worth $753,000 after purchasing an additional 46,140 shares during the last quarter. Invesco Ltd. increased its position in Xencor by 44.3% in the first quarter. Invesco Ltd. now owns 656,201 shares of the biopharmaceutical company’s stock worth $6,982,000 after purchasing an additional 201,456 shares during the last quarter. Finally, Panagora Asset Management Inc. raised its stake in Xencor by 68.4% during the second quarter. Panagora Asset Management Inc. now owns 488,892 shares of the biopharmaceutical company’s stock valued at $3,843,000 after purchasing an additional 198,564 shares in the last quarter.

Xencor Stock Performance

Shares of XNCR stock opened at $15.44 on Thursday. Xencor has a 52-week low of $6.92 and a 52-week high of $24.91. The firm has a market capitalization of $1.10 billion, a PE ratio of -8.72 and a beta of 0.96. The stock has a fifty day simple moving average of $15.49 and a two-hundred day simple moving average of $11.36.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.64. Xencor had a negative return on equity of 20.44% and a negative net margin of 87.14%.The business had revenue of $21.00 million for the quarter, compared to the consensus estimate of $29.73 million. During the same period in the previous year, the business earned ($0.71) earnings per share. The business’s revenue was up 18.0% on a year-over-year basis. On average, sell-side analysts forecast that Xencor will post -3.68 EPS for the current fiscal year.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.